{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:01:36Z","timestamp":1793037696878,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"P30 Vision Research Core Grant","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["1K12EY033745"],"award-info":[{"award-number":["1K12EY033745"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10067-025-07670-y","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T07:05:24Z","timestamp":1756969524000},"page":"3993-4003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Time to incident ocular and extraintestinal manifestation in HLA-B27-Associated diseases: a comparative study of immunotherapies"],"prefix":"10.1007","volume":"44","author":[{"given":"Negin","family":"Yavari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer F.","family":"Alsoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euna","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase A.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-7078","authenticated-orcid":false,"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"2","key":"7670_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1076\/ocii.7.2.85.4015","volume":"7","author":"EM Dodds","year":"1999","unstructured":"Dodds EM, Lowder CY, Meisler DM (1999) Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm 7(2):85\u201392","journal-title":"Ocul Immunol Inflamm"},{"key":"7670_CR2","unstructured":"Waheed, N. K. (n.d.). HLA-B27 associated uveitis. Massachusetts Eye and Ear Infirmary. Unpublished manuscript"},{"issue":"12","key":"7670_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41584-018-0097-2","volume":"14","author":"JT Rosenbaum","year":"2018","unstructured":"Rosenbaum JT, Asquith M (2018) The microbiome and HLA-B27-associated acute anterior uveitis. Nat Rev Rheumatol 14(12):704\u2013713","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"7670_CR4","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1080\/09273948.2024.2413895","volume":"32","author":"AF Alsoudi","year":"2024","unstructured":"Alsoudi AF, Wai KM, Koo E, McConnell RA, Pham NH et al (2024) Risk of intestinal complications, extraintestinal morbidity, and mortality in patients with Crohn\u2019s disease and ocular involvement. Ocul Immunol Inflamm 32(10):2486\u20132493","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"7670_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.survophthal.2005.04.003","volume":"50","author":"JH Chang","year":"2005","unstructured":"Chang JH, McCluskey PJ, Wakefield D (2005) Acute anterior uveitis and HLA-B27. Surv Ophthalmol 50(4):364\u2013388","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"7670_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4274\/tjo.galenos.2018.53896","volume":"49","author":"M \u0130nan\u00e7","year":"2019","unstructured":"\u0130nan\u00e7 M, \u015eim\u015fek M, \u00c7akar \u00d6zdal MP (2019) Etiological and clinical characteristics of HLA-B27-associated uveitis in a tertiary referral center. Turk J Ophthalmol 49(1):10\u201314","journal-title":"Turk J Ophthalmol"},{"key":"7670_CR7","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2147\/OPTH.S408728","volume":"17","author":"C Or","year":"2023","unstructured":"Or C, Lajevardi S, Ghoraba H, Park JH, Onghanseng N et al (2023) Posterior segment ocular findings in HLA-B27 positive patients with uveitis: a retrospective analysis. Clin Ophthalmol 17:1271\u20131276","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"7670_CR8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41433-022-02216-x","volume":"37","author":"HH Al-Ani","year":"2023","unstructured":"Al-Ani HH, Sims JL, Niederer RL (2023) Long term complications and vision loss in HLA-B27 uveitis. Eye 37(8):1673\u20131677","journal-title":"Eye"},{"issue":"32","key":"7670_CR9","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","volume":"23","author":"LL Troncoso","year":"2017","unstructured":"Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C (2017) Ophthalmic manifestations in patients with inflammatory bowel disease: a review. World J Gastroenterol 23(32):5836","journal-title":"World J Gastroenterol"},{"issue":"2","key":"7670_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/cells13020142","volume":"13","author":"G Migliorisi","year":"2024","unstructured":"Migliorisi G, Vella G, Dal Buono A, Gabbiadini R, Busacca A et al (2024) Ophthalmological manifestations in inflammatory bowel diseases: keep an eye on it. Cells 13(2):142","journal-title":"Cells"},{"issue":"3","key":"7670_CR11","doi-asserted-by":"publisher","first-page":"e0230560","DOI":"10.1371\/journal.pone.0230560","volume":"15","author":"N Bouzid","year":"2020","unstructured":"Bouzid N, Jamilloux Y, Chapurlat R, Pradat P, De Parisot A et al (2020) Impact of systemic treatments on the course of HLA-B27-associated uveitis: a retrospective study of 101 patients. PLoS One 15(3):e0230560","journal-title":"PLoS One"},{"issue":"10","key":"7670_CR12","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00417-018-4082-x","volume":"256","author":"MM Zu Hoerste","year":"2018","unstructured":"Zu Hoerste MM, Walscheid K, Tappeiner C, Zurek-Imhoff B, Heinz C et al (2018) The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol 256(10):1985\u20131992","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"7670_CR13","doi-asserted-by":"publisher","first-page":"otaa041","DOI":"10.1093\/crocol\/otaa041","volume":"2","author":"J Barberio","year":"2020","unstructured":"Barberio J, Kim SC, Roh M, Lewis JD, Desai RJ (2020) Risk of uveitis in patients with inflammatory bowel disease on immunosuppressive drug therapy. Crohns Colitis 360 2(3):otaa041","journal-title":"Crohns Colitis 360"},{"issue":"6","key":"7670_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJ, Aletaha D, Baraliakos X et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 83(6):706\u2013719","journal-title":"Ann Rheum Dis"},{"key":"7670_CR15","doi-asserted-by":"publisher","first-page":"1488357","DOI":"10.3389\/fimmu.2025.1488357","volume":"16","author":"F Ciccia","year":"2025","unstructured":"Ciccia F, McGonagle D, Thomas R, Marzo-Ortega H, Martin DA et al (2025) Jak inhibition and axial spondyloarthritis: new steps on the path to understanding pathophysiology. Front Immunol 16:1488357","journal-title":"Front Immunol"},{"issue":"2","key":"7670_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.MIB.0000437616.37000.41","volume":"20","author":"MH McLean","year":"2014","unstructured":"McLean MH, Neurath MF, Durum SK (2014) Targeting interleukins for the treatment of inflammatory bowel disease\u2014what lies beyond anti-TNF therapy? Inflamm Bowel Dis 20(2):389\u2013397","journal-title":"Inflamm Bowel Dis"},{"key":"7670_CR17","doi-asserted-by":"crossref","unstructured":"Bourgonje AR, Ungaro RC, Mehandru S, Colombel J-F (2024) Targeting the IL-23 pathway in inflammatory bowel disease. Gastroenterology","DOI":"10.1053\/j.gastro.2024.05.036"},{"key":"7670_CR18","doi-asserted-by":"publisher","first-page":"1393463","DOI":"10.3389\/fimmu.2024.1393463","volume":"15","author":"Z Tian","year":"2024","unstructured":"Tian Z, Zhao Q, Teng X (2024) Anti-IL23\/12 agents and JAK inhibitors for inflammatory bowel disease. Front Immunol 15:1393463","journal-title":"Front Immunol"},{"key":"7670_CR19","doi-asserted-by":"crossref","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L (2020) Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 158(6):1554\u20131573.e1512","DOI":"10.1053\/j.gastro.2020.01.001"},{"issue":"1","key":"7670_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","volume":"15","author":"S Honap","year":"2024","unstructured":"Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F et al (2024) JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol 15(1):59\u201369","journal-title":"Frontline Gastroenterol"},{"issue":"3","key":"7670_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F et al (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-psa 2. Ann Rheum Dis 80(3):312\u2013320","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"7670_CR22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Nguyen QD, Thorne JE et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932\u2013943","journal-title":"N Engl J Med"},{"issue":"7","key":"7670_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/09273948.2017.1411518","volume":"26","author":"F Mackensen","year":"2018","unstructured":"Mackensen F, Heinz C, Jakob E, Grewing V, Lorenz H-M et al (2018) Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis. Ocul Immunol Inflamm 26(7):1015\u20131022","journal-title":"Ocul Immunol Inflamm"},{"issue":"10050","key":"7670_CR24","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183\u20131192","journal-title":"Lancet"},{"key":"7670_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-021-02549-0","volume":"23","author":"D Roche","year":"2021","unstructured":"Roche D, Badard M, Boyer L, Lafforgue P, Pham T (2021) Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Res Ther 23:1\u201311","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"7670_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09273948.2016.1234625","volume":"25","author":"J Gueudry","year":"2017","unstructured":"Gueudry J, Thorne JE, Bansie R, Braun J, Van Hagen PM et al (2017) Biologic therapy for HLA-B27-associated ocular disorders. Ocul Immunol Inflamm 25(2):169\u2013178","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"7670_CR27","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ibd.21180","volume":"16","author":"DB Cury","year":"2010","unstructured":"Cury DB, Moss AC (2010) Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis 16(8):1393\u20131396","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"7670_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","volume":"13","author":"C Hedin","year":"2019","unstructured":"Hedin C, Vavricka S, Stagg A, Schoepfer A, Raine T et al (2019) The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 13(5):541\u2013554","journal-title":"J Crohns Colitis"},{"issue":"5","key":"7670_CR29","doi-asserted-by":"publisher","first-page":"e052833","DOI":"10.1136\/bmjopen-2021-052833","volume":"12","author":"D King","year":"2022","unstructured":"King D, Chandan JS, Thomas T, Denniston AK, Braithwaite T et al (2022) Risk of a subsequent diagnosis of inflammatory bowel disease in subjects with ophthalmic disorders associated with inflammatory bowel disease: a retrospective cohort analysis of UK primary care data. BMJ Open 12(5):e052833","journal-title":"BMJ Open"},{"issue":"8","key":"7670_CR30","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M et al (2015) Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 21(8):1794\u20131800","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"7670_CR31","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A et al (2015) Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 21(8):1982\u20131992","journal-title":"Inflamm Bowel Dis"},{"key":"7670_CR32","doi-asserted-by":"publisher","first-page":"933357","DOI":"10.3389\/fmed.2022.933357","volume":"9","author":"F Ferretti","year":"2022","unstructured":"Ferretti F, Monico MC, Cannatelli R, Carmagnola S, Lenti MV et al (2022) The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: a multicenter study. Front Med 9:933357","journal-title":"Front Med"},{"key":"7670_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s42358-023-00324-0","volume":"63","author":"DdR Annunciato","year":"2023","unstructured":"Annunciato DdR, Oliveira TL, Magalh\u00e3es VO, Pinheiro MdM (2023) Extra-musculoskeletal manifestations driving the therapeutic decision-making in patients with Spondyloarthritis: a 12-month follow-up prospective cohort study. Adv Rheumatology 63:44","journal-title":"Adv Rheumatology"},{"key":"7670_CR34","doi-asserted-by":"publisher","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","volume":"10","author":"C Herrera-deGuise","year":"2023","unstructured":"Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N (2023) JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases. Front Med 10:1089099","journal-title":"Front Med"},{"issue":"5","key":"7670_CR35","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s10067-022-06490-8","volume":"42","author":"F Fr\u00f6hlich","year":"2023","unstructured":"Fr\u00f6hlich F, Micheroli R, Hebeisen M, Kissling S, B\u00fcrki K et al (2023) HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry. Clin Rheumatol 42(5):1267\u20131274","journal-title":"Clin Rheumatol"},{"issue":"10214","key":"7670_CR36","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394(10214):2108\u20132117","journal-title":"Lancet"},{"key":"7670_CR37","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI et al (2022) Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis. Clin Gastroenterol Hepatol 20(8):1821\u20131830.e1823","DOI":"10.1016\/j.cgh.2020.10.038"},{"key":"7670_CR38","doi-asserted-by":"crossref","unstructured":"Zhao X, Li M, Zhang X, Tian Y, Li D et al (2025) Efficacy and Safety of IL-17 and JAK Inhibitors in Ankylosing Spondylitis: a systematic review and network meta-analysis. Int Arch Allergy Immunol","DOI":"10.1159\/000544752"},{"issue":"1","key":"7670_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12967-024-05077-y","volume":"22","author":"S Chen","year":"2024","unstructured":"Chen S, Huang W, Wan Q, Tang Z, Li X et al (2024) Investigation of the acute pathogenesis of spondyloarthritis\/HLA-B27-associated anterior uveitis based on genome-wide association analysis and single-cell transcriptomics. J Transl Med 22(1):271","journal-title":"J Transl Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07670-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:25:53Z","timestamp":1760365553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07670-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7670"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07670-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study only contained deidentified patient electronic medical records, therefore it was exempted from institutional review board approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"AK: Consultant\u2013Immunovant, Genentech, Lassen, AmGen, Acelyrin. Independent Contracted Research Viridian Therapeutics. Sling Therapeutics, Kriya Therapeutics. QDN: Consultant\u2013Genentech, Kriya Therapeutics, Regeneron. Research Support\u2013Belite Bio, Genentech, Kriya Therapeutics, Priovant, Regeneron. PM: Consultant\u2013Alcon, Amgen, Aura Biosciences, Castle Biosciences, Alcon, Genentech, Dutch Ophthalmic, Immunogen; Financial support\u2013 Genentech; Lecturer\u2013Alcon. ER: Consultant\u2013Apellis Pharmaceuticals, Iveric Bio, Genentech, Regeneron, Allergan, Zeiss, Google; Speaker\u2013Apellis Pharmaceuticals, Genentech, Regeneron, Allergan. The other authors have disclosed no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}